Optimising treatment in the test-and-treat strategy: what are we waiting for?-Reference-Cited by-同舟云学术

Optimising treatment in the test-and-treat strategy: what are we waiting for?

Published:2019-10 Issue:10 Volume:6 Page:e715-e722
ISSN:2352-3018
Container-title:The Lancet HIV
language:en
Short-container-title:The Lancet HIV

Author:

Phanuphak Nittaya,Seekaew Pich,Phanuphak Praphan

Publisher

Elsevier BV

Subject

Virology,Infectious Diseases,Immunology,Epidemiology

Reference49 articles.

1. Universal voluntary HIV testing with immediate antiretroviral therapy as a strategy for elimination of HIV transmission: a mathematical model;Granich;Lancet,2009

2. Viral load and heterosexual transmission of human immunodeficiency virus type 1. Rakai Project Study Group;Quinn;N Engl J Med,2000

3. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach,2016

4. Could widespread use of combination antiretroviral therapy eradicate Hçics?;Velasco-Hernandez;Lancet Infect Dis,2002

5. The case for expanding access to highly active antiretroviral therapy to curb the growth of the HIV epidemic;Montaner;Lancet,2006

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. HIV Phylogenetic Clusters Point to Unmet HIV Prevention, Testing and Treatment Needs Among Men Who Have Sex with Men in Kenya;2024-08-10

2. Transition times across the HIV care continuum in Spain from 2005 to 2022: a longitudinal cohort study;The Lancet HIV;2024-07

3. Physiologically‐based pharmacokinetic modelling of long‐acting injectable cabotegravir and rilpivirine in pregnancy;British Journal of Clinical Pharmacology;2024-02-10

4. Experience of the Chinese Contribution: Impact Factors of Rapid ART and its Outcome;2024

5. Experience of the Chinese Contribution: Impact Factors of Rapid ART and its Outcome;2024